Journal
CELLS
Volume 11, Issue 19, Pages -Publisher
MDPI
DOI: 10.3390/cells11193175
Keywords
carcinoma; pancreatic ductal; proto-oncogene proteins p21(ras); prognosis; survival; point mutation
Categories
Funding
- Monash Partners Comprehensive Cancer Consortium (MPCCC) research grant
- Epworth Medical Foundation (EMF) research grant
- Amgen [16584A]
Ask authors/readers for more resources
This study found that the detection of KRAS G12D mutation subtype in pancreatic ductal adenocarcinoma (PDAC) patients is not a determinant of poorer prognosis and survival. However, among resectable KRAS G12D patients, their survival was significantly shorter compared to other genotypes.
Background: KRAS G12D mutation subtype is present in over 40% of pancreatic ductal adenocarcinoma (PDAC), one of the leading global causes of cancer death. This retrospective cohort study aims to investigate whether detection of the KRAS G12D mutation subtype in PDAC patients is a determinant of prognosis across all stages of disease. Methods: We reviewed the medical records of 231 patients presenting with PDAC at a large tertiary hospital, and compared survival using the Kaplan Meier, log-rank test and Cox proportional hazards regression model. Results: KRAS G12D mutation subtype was not significantly associated with poorer survival compared across the whole population of PDAC patients (p = 0.107; HR 1.293 95% CI (0.946-1.767)). However, KRAS G12D patients who were resectable had a shorter median survival time of 356 days compared to all other genotypes (median survival 810 days) (p = 0.019; HR 1.991 95% CI (1.121-3.537)). Conclusions: KRAS G12D patients who were resectable at diagnosis had shorter survival compared to all other PDAC patients. These data suggest that KRAS G12D may be a clinically useful prognostic biomarker of PDAC.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available